Lifecore Biomedical

LFCR

Market cap $249M

CHASKA, Minn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events. Details of the company's activities at these events are as follows:

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  LifeCore between October 7, 2020, and March 19, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

Lifecore Biomedical (LFCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CHASKA, Minn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on September 22, 2025, the Lifecore compensation committee approved the grant under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) of a restricted stock unit (“RSU”) award with respect to 15,000 shares of its common stock and stock options for 30,000 shares of common stock to a newly hired employee of Lifecore. The RSU award and stock options were granted on September 22, 2025, pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore.

Lifecore Biomedical (LFCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants Paul Josephs - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Good afternoon. Thanks for joining us.

CHASKA, Minn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 24th Annual Contract Pharma Contracting and Outsourcing Conference. Recognized as one of the top annual events for pharmaceutical outsourcing and contract manufacturing, the Contract Pharma conference will take place September 18-19, 2025, in New Brunswick, NJ.

CHASKA, Minn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences. Details regarding Lifecore's participation are as follows:

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In LifeCore (LFCR) To Contact Him Directly To Discuss Their Options

Universal Electronics Inc. (UEIC) Q4 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Paul Josephs - President, CEO & Director Ryan D. Lake - EVP & CFO Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Maxwell Andrew Smock - William Blair & Company L.L.C.